IMI 2 Info Day Indicative Call Topics
RADAR Remote assessment of disease and relapse Theo Meert, Senior Director External Innovations NS, Janssen Research & Development, J&J. Assessing risk and progression of pre-diabetes and type 2 diabetes to enable disease modification
Bernd Stowasser, Head of European Public Partnerships, Sanofi-Aventis. Towards a quantitative biological approach for neuropsychiatry. Overview – EFPIA Representative Hugh Marsten, Head of In Vivo Pharmacology, Eli Lilly. Questions & Answers Moderated by Elisabetta Vaudano, Scientific Pillar Coordinator, IMI.